Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
Go back to Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study| (NASDAQ: CNTB) | Delayed: 0.97 -0.13 (11.82%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.10 | 52 Week High | $ | |||
| Open | $1.12 | 52 Week Low | $ | |||
| Day High | $1.12 | P/E | N/A | |||
| Day Low | $0.94 | EPS | $ | |||
| Volume | 7,166,163 | |||||
